Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezacaftor/Ivacaftor in Orkambi-experienced CF patients
NCT03150719Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing TEZ/IVA with Placebo (2 arms). Primary endpoint: Incidence of Respiratory Adverse Events of Special Interest. Started May 2017; status: completed.
02
Drugs
tezacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03150719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150719.